M&As this week: Shanghai Fosun Pharmaceutical, Pfizer and Luminex

19th May 2016 (Last Updated May 19th, 2016 18:30)

Shanghai Fosun Pharmaceutical, a biopharmaceutical and healthcare company, plans to develop its drug manufacturing and R&D capacity by acquiring Gland Pharma, an Indian pharmaceutical company.

Shanghai Fosun Pharmaceutical, a biopharmaceutical and healthcare company, plans to develop its drug manufacturing and R&D capacity by acquiring Gland Pharma, an Indian pharmaceutical company.

The sale consideration is estimated to be between $1bn and $1.5bn.

Pfizer has announced that it will acquire Anacor Pharmaceuticals to expand and strengthen its business and develop atopic dermatitis, inflammation and immunology portfolio. The consideration is expected to be approximately $5.2bn.

It has further announced that following the acquisition, Quattro Merger, a wholly-owned subsidiary of Pfizer will be merged into Anacor, which will be a new wholly-owned subsidiary of Pfizer.

"Pfizer has announced that it will acquire Anacor Pharmaceuticals to expand and strengthen its business and develop atopic dermatitis, inflammation and immunology portfolio."

Centerview Partners and Guggenheim Securities are acting as financial advisors, while Wachtell, Lipton, Rosen & Katz are acting as legal advisors to the acquirer.

Citigroup Inc. is acting as financial advisor and Davis Polk & Wardwell are acting as legal advisors for the target company.

Luminex has entered a definitive agreement to acquire Nanosphere to accelerate its growth in new markets and develop its pipeline products and product portfolio.

The sale consideration is expected to be approximately $83m, which will be totally funded by Luminex through cash in hand.

Perella Weinberg Partners is acting as financial advisor and Gambell & Russell is acting as outside counsel to Luminex, while Jefferies LLC is acting as financial advisor and Seyfarth Shaw is acting as outside counsel to Nanosphere.

The transaction is expected to be completed by July 2016.